LEMD2

Across TCGA pan-cancer cohorts, LEMD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LEMD2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LEMD2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LEMD2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

UCEC, HNSC, and CCRCC are the cancer types where LEMD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.494	1.000	.016	24	view →
HNSC	DFS	Median	II,III,IV	0.993	0.897	.005	14	view →
CCRCC	DFS	Median	III,IV	0.783	0.379	.003	13	view →
PDAC	OS	Median	IV	0.937	0.395	.026	6	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LEMD2–UCEC (OS)

Open the UCEC breakdown →